Clinical bottom line
Novel oral cardiac myosin inhibitors represent a promising therapeutic advance for patients with hypertrophic cardiomyopathy (HCM), particularly those with symptomatic obstructive disease. Current evidence suggests these agents can reduce left ventricular outflow tract (LVOT) gradients, improve symptoms, and enhance exercise capacity. While early data are encouraging, longer-term outcomes and effects in diverse patient subgroups require further validation.
What the evidence shows
Bittencourt et al. (2026) provide a comprehensive review of cardiac myosin inhibitors in HCM, highlighting their mechanism of action targeting hypercontractility by modulating myosin-actin interactions. Clinical trials demonstrate significant reductions in LVOT obstruction and symptom burden.
Yassen et al. (2023) conducted a placebo-controlled trial showing that cardiac myosin inhibitors significantly improved functional status and reduced LVOT gradients in symptomatic HCM patients. These findings were corroborated by an earlier abstract from Yassen et al. (2022), which reported consistent efficacy and tolerability.
Masri et al. (2022) emphasized the novel mechanism addressing the core pathophysiology of obstructive HCM, contrasting with traditional therapies that primarily target symptoms rather than contractile abnormalities.
Sikand et al. (2024) explored the use of cardiac myosin inhibitors in patients with obstructive HCM and comorbid hypertension, suggesting that these agents remain effective without adversely impacting blood pressure control, an important consideration in this population.
Haraf et al. (2024) reviewed the evolving landscape of HCM management, positioning cardiac myosin inhibitors as a potential alternative or adjunct to invasive septal reduction therapies, with favorable safety profiles.
Caveats and uncertainty
Most data derive from relatively short-term clinical trials with limited follow-up, leaving long-term safety and durability of benefit uncertain.
Patient populations in trials have been carefully selected, and real-world effectiveness in broader, more heterogeneous cohorts is not yet established.
Potential drug interactions and effects in patients with nonobstructive HCM phenotypes remain underexplored.
Cost and access considerations may limit widespread adoption initially.
How this may change practice
Cardiac myosin inhibitors may become a first-line pharmacologic option for symptomatic obstructive HCM, potentially reducing the need for invasive procedures.
Clinicians should consider these agents for patients inadequately controlled with beta-blockers or calcium channel blockers.
Ongoing monitoring for efficacy and adverse effects will be essential as clinical experience grows.
Multidisciplinary collaboration including cardiologists specialized in HCM will facilitate optimal patient selection and management.
Future guidelines are likely to incorporate cardiac myosin inhibitors as standard therapy pending confirmatory long-term data.